SAM
ADVM

Stenahm Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Stenahm Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,100
Closed -$1.09M – 28
2021
Q1 		$1.09M Sell
11,100
-11,100
-50% -$1.33M 0.77% 21
2020
Q4 		$2.41M Buy
+22,200
New +$2.75M 2.02% 16

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Stenahm Asset Management's ADVM Position: Q2 2021 in Review

Stenahm Asset Management sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 11,100 shares — an estimated $1.09M sold.

Stenahm Asset Management first reported a position in ADVM in Q4 2020 and held it in 2 quarters. The position peaked at $2.41M in Q4 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Stenahm Asset Management reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Stenahm Asset Management sold 11,100 Adverum Biotechnologies shares in Q2 2021, an estimated $1.09M.
  • Stenahm Asset Management first reported a position in Adverum Biotechnologies in Q4 2020 and held it in 2 quarters.
  • Stenahm Asset Management's Adverum Biotechnologies position peaked at $2.41M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Stenahm Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.